Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed)

Funding Opportunity RFA-EY-21-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative. This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. These cell lines and clinical data are from patients with AMD carrying high prevalence risk alleles selected from the Age-Related Eye Disease Study 2 (AREDS2). The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects.
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding